RATIONALE: Cannabidiol, the main nonpsychotropic constituent of Cannabis sativa, possesses a large number of pharmacological effects including anticonvulsive, sedative, hypnotic, anxiolytic, antipsychotic, anti-inflammatory, and neuroprotective, as demonstrated in clinical and preclinical studies. Many neurodegenerative disorders involve cognitive deficits, and this has led to interest in whether cannabidiol could be useful in the treatment of memory impairment associated to these diseases. OBJECTIVES: We used an animal model of cognitive impairment induced by iron overload in order to test the effects of cannabidiol in memory-impaired rats. METHODS: Rats received vehicle or iron at postnatal days 12-14. At the age of 2 months, they received an acute intraperitoneal injection of vehicle or cannabidiol (5.0 or 10.0 mg/kg) immediately after the training session of the novel object recognition task. In order to investigate the effects of chronic cannabidiol, iron-treated rats received daily intraperitoneal injections of cannabidiol for 14 days. Twenty-four hours after the last injection, they were submitted to object recognition training. Retention tests were performed 24 h after training. RESULTS: A single acute injection of cannabidiol at the highest dose was able to recover memory in iron-treated rats. Chronic cannabidiol improved recognition memory in iron-treated rats. Acute or chronic cannabidiol does not affect memory in control rats. CONCLUSIONS: The present findings provide evidence suggesting the potential use of cannabidiol for the treatment of cognitive decline associated with neurodegenerative disorders. Further studies, including clinical trials, are warranted to determine the usefulness of cannabidiol in humans suffering from neurodegenerative disorders.
RATIONALE: Cannabidiol, the main nonpsychotropic constituent of Cannabis sativa, possesses a large number of pharmacological effects including anticonvulsive, sedative, hypnotic, anxiolytic, antipsychotic, anti-inflammatory, and neuroprotective, as demonstrated in clinical and preclinical studies. Many neurodegenerative disorders involve cognitive deficits, and this has led to interest in whether cannabidiol could be useful in the treatment of memory impairment associated to these diseases. OBJECTIVES: We used an animal model of cognitive impairment induced by iron overload in order to test the effects of cannabidiol in memory-impairedrats. METHODS:Rats received vehicle or iron at postnatal days 12-14. At the age of 2 months, they received an acute intraperitoneal injection of vehicle or cannabidiol (5.0 or 10.0 mg/kg) immediately after the training session of the novel object recognition task. In order to investigate the effects of chronic cannabidiol, iron-treated rats received daily intraperitoneal injections of cannabidiol for 14 days. Twenty-four hours after the last injection, they were submitted to object recognition training. Retention tests were performed 24 h after training. RESULTS: A single acute injection of cannabidiol at the highest dose was able to recover memory in iron-treated rats. Chronic cannabidiol improved recognition memory in iron-treated rats. Acute or chronic cannabidiol does not affect memory in control rats. CONCLUSIONS: The present findings provide evidence suggesting the potential use of cannabidiol for the treatment of cognitive decline associated with neurodegenerative disorders. Further studies, including clinical trials, are warranted to determine the usefulness of cannabidiol in humans suffering from neurodegenerative disorders.
Authors: Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry Journal: Br J Pharmacol Date: 2011-04 Impact factor: 8.739
Authors: Maria Noêmia M de Lima; Daniela C Laranja; Fábio Caldana; Elke Bromberg; Rafael Roesler; Nadja Schröder Journal: Exp Gerontol Date: 2005-04-02 Impact factor: 4.032
Authors: Moisés García-Arencibia; Sara González; Eva de Lago; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz Journal: Brain Res Date: 2006-12-28 Impact factor: 3.252
Authors: Maria Noemia M de Lima; Manuela Polydoro; Daniela C Laranja; Fernanda Bonatto; Elke Bromberg; José Cláudio F Moreira; Felipe Dal-Pizzol; Nadja Schröder Journal: Eur J Neurosci Date: 2005-05 Impact factor: 3.386
Authors: Omar J Cassol; Clarissa M Comim; Bruno R Silva; Fernanda V Hermani; Larissa S Constantino; Francine Felisberto; Fabricia Petronilho; Jaime Eduardo C Hallak; Bruno S De Martinis; Antonio W Zuardi; José A S Crippa; João Quevedo; Felipe Dal-Pizzol Journal: Brain Res Date: 2010-06-16 Impact factor: 3.252
Authors: Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss Journal: Neuropsychopharmacology Date: 2018-03-22 Impact factor: 7.853
Authors: Vanessa Kappel da Silva; Betânia Souza de Freitas; Arethuza da Silva Dornelles; Laura Roesler Nery; Lucio Falavigna; Rafael Dal Ponte Ferreira; Maurício Reis Bogo; Jaime Eduardo Cecílio Hallak; Antônio Waldo Zuardi; José Alexandre S Crippa; Nadja Schröder Journal: Mol Neurobiol Date: 2013-07-28 Impact factor: 5.590
Authors: Patrícia Schönhofen; Liana M de Medeiros; Ivi Juliana Bristot; Fernanda M Lopes; Marco A De Bastiani; Flávio Kapczinski; José Alexandre S Crippa; Mauro Antônio A Castro; Richard B Parsons; Fábio Klamt Journal: Mol Neurobiol Date: 2014-08-10 Impact factor: 5.590
Authors: Douglas L Boggs; Toral Surti; Aarti Gupta; Swapnil Gupta; Mark Niciu; Brian Pittman; Ashley M Schnakenberg Martin; Halle Thurnauer; Andrew Davies; Deepak C D'Souza; Mohini Ranganathan Journal: Psychopharmacology (Berl) Date: 2018-04-05 Impact factor: 4.530